CFTR gene therapy (UK Cystic Fibrosis Gene Therapy Consortium/ID Pharma)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCFTR gene therapy (UK Cystic Fibrosis Gene Therapy Consortium/ID Pharma)
Drug Alias NameCFTR gene therapy (UK Cystic Fibrosis Gene Therapy Consortium/ID Pharma)SeV-CFTR gene therapy (UK Cystic Fibrosis Gene Therapy consortium/DNAVEC)lentiviral-based gene therapy (UK Cystic Fibrosis Gene Therapy Consortium/DNAVEC)
ClassificationBiologics
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator stimulants
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUk Cystic Fibrosis Gene Therapy Consortium
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesID Pharma Co LtdUk Cystic Fibrosis Gene Therapy Consortium
Active IndicationsN/A
Inactive IndicationsCystic Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A